ISABELLE LE POOLE

Summary

Affiliation: Loyola University Medical Center
Country: USA

Publications

  1. pmc 'VIT1', a novel gene associated with vitiligo
    I C Le Poole
    Department of Pathology, Loyola University Chicago, Illinois 60513, USA
    Pigment Cell Res 14:475-84. 2001
  2. ncbi request reprint Recent progress in tumour vaccine development
    I Caroline Le Poole
    Oncology Institute, Loyola University Medical Center, 2160 S 1st Ave, Maywood, IL 60153, USA
    Expert Opin Investig Drugs 12:971-81. 2003
  3. ncbi request reprint Advances in prophylactic cancer vaccine research
    I Caroline Le Poole
    Cancer Immunology Program, Cardinal Bernardin Cancer Center, Maywood, IL 60153, USA
    Expert Rev Anticancer Ther 3:537-45. 2003
  4. doi request reprint Autoimmune etiology of generalized vitiligo
    I Caroline Le Poole
    Department of Pathology, Oncology Institute, Loyola University, Chicago, IL, USA
    Curr Dir Autoimmun 10:227-43. 2008
  5. pmc Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells
    I Caroline Le Poole
    Department of Pathology, Skin Oncology Research Program, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Bldg 112, Rm 303, 2160 S 1st Ave, Maywood, IL 60153, USA
    Am J Pathol 160:521-8. 2002
  6. ncbi request reprint Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin
    I C Le Poole
    Department of Pathology, Cardinal Bernardin Cancer Center Rm 203, Loyola University, 2160 South First Avenue, Maywood, Chicago, IL 60153, U S A
    Br J Dermatol 149:739-48. 2003
  7. ncbi request reprint Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells
    I Caroline Le Poole
    Department of Pathology Oncology Institute, Loyola University Medical Center, Bldg 112, Rm 203, 2160 South 1st Ave, Maywood, IL 60153, USA
    Cancer Immunol Immunother 57:789-97. 2008

Research Grants

  1. Stress proteins in autoimmune depigmentation
    ISABELLE LE POOLE; Fiscal Year: 2005
  2. Targeting HSP70 in autoimmune vitiligo
    ISABELLE CAROLINE LE POOLE; Fiscal Year: 2010
  3. Targeting HSP70 in autoimmune vitiligo
    ISABELLE LE POOLE; Fiscal Year: 2009
  4. Pigmentation and Diversity Conference
    ISABELLE LE POOLE; Fiscal Year: 2007
  5. Autoimmune vitiligo as a roadmap to melanoma therapy
    ISABELLE LE POOLE; Fiscal Year: 2007
  6. Chemopreventive treatment of familial melanoma
    ISABELLE LE POOLE; Fiscal Year: 2007
  7. Autoimmune vitiligo as a roadmap to melanoma therapy
    ISABELLE LE POOLE; Fiscal Year: 2006
  8. Autoimmune vitiligo as a roadmap to melanoma therapy
    ISABELLE LE POOLE; Fiscal Year: 2005
  9. Modulating tolerance in a spontaneous mouse model of autoimmune vitiligo
    ISABELLE CAROLINE LE POOLE; Fiscal Year: 2010

Detail Information

Publications7

  1. pmc 'VIT1', a novel gene associated with vitiligo
    I C Le Poole
    Department of Pathology, Loyola University Chicago, Illinois 60513, USA
    Pigment Cell Res 14:475-84. 2001
    ..Expression of ORF mRNA was confirmed for multiple skin cell types, suggesting its importance for skin physiology...
  2. ncbi request reprint Recent progress in tumour vaccine development
    I Caroline Le Poole
    Oncology Institute, Loyola University Medical Center, 2160 S 1st Ave, Maywood, IL 60153, USA
    Expert Opin Investig Drugs 12:971-81. 2003
    ..Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer...
  3. ncbi request reprint Advances in prophylactic cancer vaccine research
    I Caroline Le Poole
    Cancer Immunology Program, Cardinal Bernardin Cancer Center, Maywood, IL 60153, USA
    Expert Rev Anticancer Ther 3:537-45. 2003
    ..This paper addresses the specific challenges posed to the exciting field of prophylactic cancer vaccine research...
  4. doi request reprint Autoimmune etiology of generalized vitiligo
    I Caroline Le Poole
    Department of Pathology, Oncology Institute, Loyola University, Chicago, IL, USA
    Curr Dir Autoimmun 10:227-43. 2008
    ..The resulting efficacious and progressive autoimmune response to melanocytes provides a roadmap for melanoma therapy...
  5. pmc Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells
    I Caroline Le Poole
    Department of Pathology, Skin Oncology Research Program, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Bldg 112, Rm 303, 2160 S 1st Ave, Maywood, IL 60153, USA
    Am J Pathol 160:521-8. 2002
    ..Reduced MART-1 expression was frequently observed in adjacent tumor cells. Consequently, IFN-gamma may enhance inflammatory responses yet hamper effective recognition of melanoma cells...
  6. ncbi request reprint Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin
    I C Le Poole
    Department of Pathology, Cardinal Bernardin Cancer Center Rm 203, Loyola University, 2160 South First Avenue, Maywood, Chicago, IL 60153, U S A
    Br J Dermatol 149:739-48. 2003
    ..Expression of CDw60 by keratinocytes is defined by the presence of T-helper cell (Th)1 vs. Th2 cytokines, and can serve as a sentinel molecule to characterize an ongoing skin immune response...
  7. ncbi request reprint Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells
    I Caroline Le Poole
    Department of Pathology Oncology Institute, Loyola University Medical Center, Bldg 112, Rm 203, 2160 South 1st Ave, Maywood, IL 60153, USA
    Cancer Immunol Immunother 57:789-97. 2008
    ..Shrinkage of HPV16 E6 and E7 expressing tumors correlated with infiltration by S100+ DC and LC, co-localizing with apoptotic mouse tumor cells. In conclusion, DC and LC mediated killing may be exploitable for anti-tumor treatment...

Research Grants11

  1. Stress proteins in autoimmune depigmentation
    ISABELLE LE POOLE; Fiscal Year: 2005
    ..The same model will be of use to test the efficacy of therapeutic modalities to be developed for vitiligo in the future. ..
  2. Targeting HSP70 in autoimmune vitiligo
    ISABELLE CAROLINE LE POOLE; Fiscal Year: 2010
    ..Here we propose to explore the mechanism and the merit of blocking HSP70 from activating an immune response in order to halt disease progression in our newly established model of autoimmune vitiligo. ..
  3. Targeting HSP70 in autoimmune vitiligo
    ISABELLE LE POOLE; Fiscal Year: 2009
    ..Here we propose to explore the mechanism and the merit of blocking HSP70 from activating an immune response in order to halt disease progression in our newly established model of autoimmune vitiligo. ..
  4. Pigmentation and Diversity Conference
    ISABELLE LE POOLE; Fiscal Year: 2007
    ....
  5. Autoimmune vitiligo as a roadmap to melanoma therapy
    ISABELLE LE POOLE; Fiscal Year: 2007
    ..Importantly, the cloning of high affinity T cell receptors in retroviral vectors may be suitable for introduction into patient PBL for treatment of malignant melanoma. ..
  6. Chemopreventive treatment of familial melanoma
    ISABELLE LE POOLE; Fiscal Year: 2007
    ..3] To quantify melanoma tumor growth and measure immunologic parameters (cytokine secretion by ELISA and ELISPOT) in mice treated with bleaching agents and IL-2. ..
  7. Autoimmune vitiligo as a roadmap to melanoma therapy
    ISABELLE LE POOLE; Fiscal Year: 2006
    ..Importantly, the cloning of high affinity T cell receptors in retroviral vectors may be suitable for introduction into patient PBL for treatment of malignant melanoma. ..
  8. Autoimmune vitiligo as a roadmap to melanoma therapy
    ISABELLE LE POOLE; Fiscal Year: 2005
    ..Importantly, the cloning of high affinity T cell receptors in retroviral vectors may be suitable for introduction into patient PBL for treatment of malignant melanoma. ..
  9. Modulating tolerance in a spontaneous mouse model of autoimmune vitiligo
    ISABELLE CAROLINE LE POOLE; Fiscal Year: 2010
    ....